Positions

Overview

  • James A. Bonner, M.D., is Senior Advisor to the Director of the UAB Comprehensive Cancer Center and the Merle M. Salter Endowed Chair in Radiation Oncology. A member of the UAB faculty since 1998, Dr. Bonner served as co-leader of the Cancer Center’s Experimental Therapeutics Program from 1998 to 2010.

    Dr. Bonner received his undergraduate degree from Duke University and his M.D. from Wayne State University. His research interest focuses on methods of enhancing radiosensitization such as combinations of chemotherapy or targeted therapy with radiotherapy. His current laboratory interests are directed at the development of single chain antibodies that target the epidermal growth factor receptor and can be delivered in a gene therapy approach.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Differential escape mechanisms in cetuximab-resistant head and neck cancer cells 2019
    2019 Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies 2019
    2019 Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century 2019
    2019 Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma 2019
    2019 A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck 2019
    2019 Treatment intensity in locoregionally advanced head and neck cancer: Recent investigation leads to new questions 2019
    2018 In Regard to Bossi et al 2018
    2018 Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations 2018
    2018 A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer 2018
    2018 Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative 2018
    2018 Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis 2018
    2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage 2018
    2017 Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer 2017
    2017 Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs 2017
    2017 p16, HPV, and cetuximab: What is the evidence? 2017
    2017 In reply 2017
    2017 Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522 2017
    2016 Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neck 2016
    2016 Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy. 2016
    2016 Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy. 2016
    2016 Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial 2016
    2016 Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx a secondary analysis of a randomized clinical trial 2016
    2016 Management of Advanced Head and Neck Cancer 2016
    2016 The authors reply 2016
    2016 Correction: Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine (PLoS ONE (2016) 9:12 (e116388) DOI: 10.1371/journal.pone.0116388) 2016
    2016 Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: Recent results 2016
    2016 Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or Without Cetuximab 2016
    2016 Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: Evidence from a case study 2016
    2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition 2015
    2015 Society of chairs of academic radiation oncology programs-endorsed radiation oncology department review process 2015
    2015 DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma 2015
    2015 Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity 2015
    2014 Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine 2014
    2014 Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 2014
    2014 Pazopanib combined with radiation: In vivo model of interaction 2014
    2014 Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology 2014
    2014 African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis 2014
    2014 Burnout in United States academic chairs of radiation oncology programs 2014
    2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines 2014
    2013 Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute 2013
    2013 Patterns of prophylactic gastrostomy tube placement in head and neck cancer patients: A consideration of the significance of social support and practice variation 2013
    2013 Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer 2013
    2013 Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients 2013
    2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy 2013
    2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy 2013
    2012 Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies 2012
    2012 HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair 2012
    2012 Feasibility of exercising adults with asthma: a randomized pilot study 2012
    2012 Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis 2012
    2012 Kinomic profiling approach identifies Trk as a novel radiation modulator 2012
    2012 MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma 2012
    2012 Gastrostomy tube placement and use in patients with head and neck cancer 2012
    2012 Small-cell lung cancer: Prognostic factors and changing treatment over 15 years 2012
    2011 Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer 2011
    2011 Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx 2011
    2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation 2011
    2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancer 2011
    2011 Dosimetric impact of target definitions on normal structures in head and neck cancer 2011
    2011 Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma 2011
    2011 The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy 2011
    2011 Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: A comprehensive review and call for evidence-based medicine 2011
    2011 Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancer 2011
    2011 Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy 2011
    2011 Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214 2011
    2011 Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis 2011
    2011 Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. 2011
    2011 Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients 2011
    2010 Comparison of Methods to Reduce Dose to Swallowing-Related Structures in Head and Neck Cancer 2010
    2010 RapidArc Radiation Therapy: First Year Experience at the University of Alabama at Birmingham 2010
    2010 Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy 2010
    2010 Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck 2010
    2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
    2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival 2010
    2009 Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma 2009
    2009 Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients 2009
    2009 Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer 2009
    2009 EGFR FISH as a predictive factor for selection of patients with non-small cell lung cancer treated with cetuximab and chemotherapy 2009
    2008 Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment 2008
    2008 Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers 2008
    2007 Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?: Commentary 2007
    2007 Design and development of water-soluble curcumin conjugates as potential anticancer agents 2007
    2007 The authors reply [8] 2007
    2007 More on severe cutaneous reaction with radiotherapy and cetuximab [13] 2007
    2007 Biology of interactions: Antiepidermal growth factor receptor agents 2007
    2007 Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53) 2007
    2007 Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab 2007
    2007 A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734 2007
    2007 Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology 2007
    2006 Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy 2006
    2006 The authors and a colleague reply [11] 2006
    2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck 2006
    2006 Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients 2006
    2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study 2006
    2005 Patterns of surgical care of lung cancer patients 2005
    2005 Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly 2005
    2005 Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base 2005
    2005 SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment Planing 2005
    2004 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure 2004
    2004 Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer 2004
    2004 Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models 2004
    2004 Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells 2004
    2004 Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression 2004
    2004 Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis 2004
    2003 The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly 2003
    2003 Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody 2003
    2003 Intraoperative radiotherapy for head and neck and skull base cancer 2003
    2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery 2003
    2003 Validation of target volume and position in respiratory gated CT planning and treatment 2003
    2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation 2002
    2002 Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer 2002
    2002 Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 2002
    2002 Epidermal growth factor receptor as a therapeutic target in head and neck cancer. 2002
    2002 A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot 2002
    2002 Adjuvant radiation therapy after complete resection of non-small-cell lung cancer [3] (multiple letters) 2002
    2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy. 2002
    2002 A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer 2002
    2002 Effect of multileaf collimator leaf width on physical dose distributions in the treatment of CNS and head and neck neoplasms with intensity modulated radiation therapy 2002
    2002 Epidermal growth factor receptor as a therapeutic target in head and neck cancer 2002
    2002 The possible use of uniform PORT doses is important in the SEER analysis, but undetected selection bias remains an issue 2002
    2001 Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer 2001
    2001 Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicity 2001
    2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer 2001
    2001 Commentary "effectiveness of therapy on non-small-cell lung cancer" 2001
    2000 Sensitivity and action of etoposide on malignant glioma cell lines 2000
    2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. 2000
    2000 A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fractures 2000
    2000 A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer 2000
    2000 Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer 2000
    2000 Non-small cell lung cancer: Introduction 2000
    2000 Point: The potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer 2000
    2000 Postoperative irradiation in non-small cell lung cancer 2000
    2000 Unresectable or medically inoperable non-small cell lung cancer: The use of established clinical prognostic factors in making radiation-related treatment decisions 2000
    1999 Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes 1999
    1999 Factors predicting patterns of recurrence after resection of N1 non- small cell lung carcinoma 1999
    1999 Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma 1999
    1999 Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma. 1999
    1999 Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: Implications related to the design of clinical trials 1999
    1999 Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma 1999
    1999 Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer 1999
    1999 The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: Seeking to optimize local control and survival while minimizing toxicity 1999
    1999 The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity. 1999
    1999 Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three- dimensional dose-escalation settings 1999
    1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation 1999
    1999 Current guidelines for the management of small cell lung cancer 1999
    1999 Sensitivity and action of etoposide on malignant glioma cell lines 1999
    1998 Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells 1998
    1998 Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces 1998
    1998 Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: Improved local-regional disease control compared with surgery alone 1998
    1998 The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma 1998
    1998 The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. 1998
    1998 Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: A matched-pair analysis 1998
    1998 Spinal cord localization in the treatment of lung cancer: Use of radiographic landmarks 1998
    1998 Bronchial carcinoid tumors: Importance of prognostic factors that influence patterns of recurrence and overall survival 1998
    1997 Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer? 1997
    1997 Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer? 1997
    1997 Etoposide sensitivity of radioresistant human glioma cell lines 1997
    1997 The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement 1997
    1997 The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. 1997
    1997 Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma 1997
    1997 Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. 1997
    1997 Laryngeal chondrosarcomas: The Mayo Clinic experience 1997
    1997 Laryngeal chondrosarcomas: the Mayo Clinic experience. 1997
    1997 Postoperative localization of porta hepatis and abdominal vasculature in pancreatic malignancies: Implications for postoperative radiotherapy planning 1997
    1997 Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks 1997
    1996 The significance of the sequence of administration of topotecan and etoposide 1996
    1996 The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11. 1996
    1996 Radiation therapy for glottic cancer using 6-MV photons [5] 1996
    1996 Radiation therapy for glottic cancer using 6-MV photons 1996
    1996 Radiation therapy for glottic cancer using 6-MV photons. 1996
    1996 The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11 1996
    1995 Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer. 1995
    1995 Assessing the Interaction of Irradiation With Etoposide or Idarubicin 1995
    1995 Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer 1995
    1995 Management of stage ie primary gastric lymphoma 1995
    1995 Prophylactic cranial irradiation in limited‐stage small cell lung cancer 1995
    1994 Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapy 1994
    1994 The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities 1994
    1994 Topoisomerase II-independent doxorubicin-induced cytotoxicity in an extremely doxorubicin-resistant cell line 1994
    1994 Treatment of stage ie primary lymphoma of bone 1994
    1994 Etoposide-resistance in the multidrug-resistant LZ-8 cells 1994
    1994 Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy 1994
    1994 Postoperative adjuvant therapy for non-small cell lung cancer: a consensus report 1994
    1994 Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report 1994
    1993 Malignant tracheoesophageal fistula in patients with esophageal cancer 1993
    1993 Role of Radiation Therapy in the Management of Lung Cancer 1993
    1993 The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment 1993
    1992 Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin 1992
    1990 Doxorubicin decreases the repair of radiation-induced DNA damage 1990
    1989 Protection of doxorubicin cytotoxicity by cycloheximide 1989
    1988 The management of vaginal melanoma 1988

    Chapter

    Year Title Altmetric
    2015 Interaction of Chemotherapy and Radiation.  63-79.e4. 2015
    2015 Nasopharyngeal Carcinoma.  629-648.e4. 2015
    2011 Interaction of Chemotherapy and Radiation.  65-82. 2011
    2011 Nasopharyngeal Carcinoma.  619-638. 2011
    2006 Molecular Targets for Radiosensitization.  391-414. 2006

    Research Overview

  • Major Research Interests:
    1. The interaction of radiation and novel chemotherapeutic and biological agents.
    2. Gene therapy delivery of anti-EGFr single chain antibodies.

    • Principal Investigator On

  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2011 - 2012

    • Investigator On

    Teaching Overview

  • TEACHING EXPERIENCE

    1. Radiation Oncology Residency Program (Participant in formal clinical and radiobiology lectures as well as daily “bedside” discussions concerning patient management), Mayo Clinic and UAB.

    2. Mayo Radiation Oncology Technology Program Radiobiology Lectures, 1990 – 1997.

    3. Director of Mayo Radiation Oncology Monthly Clinical Journal Club, 1991 – 1998.

    4. Awards received by residents who performed laboratory rotations: K. Minehan (recipient of ASTRO residents essay award for laboratory project), E. Durr (recipient of Radiation Research Society Travel Award), T. Sawyer (recipient of Morton Fellowship for laboratory project), R. Miller (recipient of ASTRO resident essay award for laboratory project, recipient of Morton Fellowship for laboratory project, recipient of American Radium Society residents essay award)

    5. Course director for Mayo Graduate School Course 5150su: Introductory Radiation Biology (Biophysics Sciences: 2 semester credits), 1995 – 1998 – designed entire semester course and taught a large portion of the course.

    6. Lecturer in the Tumor Biology Graduate School Program, Mayo Clinic, Rochester, MN, 1995 – 1998.

    7. Primary Director of First, Second and Third Annual Radiation Oncology Symposia in Scottsdale, Arizona - February 1997, February 1998, February 1999, respectively (collaboration with the Mayo Clinic): worked with CME office to set objectives, select faculty, organize teleconferences with faculty and moderated the Program. Also, obtained pharmaceutical company support for the project.

    8. Co-Director of the Fourth Annual Radiation Oncology Symposium in Orlando, Florida – July 2000 (collaboration with The University of Michigan): similar duties as first – third symposiums which were done in collaboration with the Mayo Clinic.

    9. Residency Director for the Department of Radiation Oncology at UAB, April 1998 – April 2001. The program was somewhat in disarray due to lack of faculty and no Department Chairman for three years. Worked to recruit excellent residents and build the educational component of the program. We started a core curriculum of 52 lectures per year. This core curriculum was intended to cover all major cancer treatments. This program exists today.

    10. Co-Director of Translational Research meeting sponsored by the American Society of Therapeutic Radiology (ASTRO): San Francisco, CA – August 5 – 6, 2005.

    11. Numerous co-director positions for CME courses (see invited presentations): 2005 – Present, (most recently co-director of International HPV in Cancer Conference, Amsterdam, November 2010. Sponsored by Lancet Oncology).

    • Full Name

  • James Bonner